The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Stalicla, a privately-held Swiss biotech developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders such as autism spectrum disorder, has named Purnanand Sarma as chair of its board of directors. 9 July 2024
US biotech Moderna and Japan’s Mitsubishi Tanabe Pharma have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax. 9 July 2024
While investors await the outcome of a head-to-head trial featuring GLP-1 heavyweights semaglutide and tirzepatide, a large retrospective observational study points to a likely winner. 9 July 2024
Boston, USA-based clinical-stage biopharma company HilleVax saw its shares plummet more than 88% to $1.64 by lose of trading on Monday as it pulled the plug on its lead vaccine candidate in infants. 9 July 2024
Privately-held UK biotech Curve Therapeutics today announced the appointment of Simon Jones to the posts of chief financial (CFO) and chief operating officer (COO) of the company. 9 July 2024
UK-based MedPharm, an Ampersand Capital Partners portfolio company, and the US firm Tergus Pharma, a Great Point Partners portfolio company, have jointly announced they are merging. 9 July 2024
California’s IDEAYA Biosciences (Nasdaq: IDYA), a precision medicine oncology firm, has announced promising Phase II data for IDE397, lifting shares in the firm by around 15%. 9 July 2024
US pharma major Eli Lilly is to acquire Morphic (Nasdaq: MORF), a US biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, for $3.2 billion. 8 July 2024
Florida, USA-based Ligand Pharmaceuticals today announced that it has entered into a definitive agreement to acquire privately-held Austrian company Aperion Biologics. 8 July 2024
Kineta saw its shares rise almost 30% to $0.79 in pre-market activity, on news that it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences. 8 July 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has announced the appointment of Paul Carter as chair of the board of directors. 8 July 2024
Ascentage Pharma yesterday announced that olverembatinib has been approved by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region (SAR) of China. 8 July 2024
OnabotulinumtoxinA (BoNT-A) and monoclonal antibodies against the calcitonin gene-related protein (anti-CGRP MAbs) have emerged as the first disease-specific preventative treatments to be approved for chronic migraine. 8 July 2024
China’s National Medical Products Administration (NMPA) has approved Xpovio (selinexor), from Antengene Corp as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). 8 July 2024
The European Federation of Pharmaceutical Industries and Associations (EFPIA) noted in a posting on its website that European Union legislation will shape the future pf research, development and manufacturing in Europe for decades to come. 8 July 2024